INNT

Innovate Biopharmaceuticals Inc

Healthcare


Presented:05/11/2018
Price:$16.76
Cap:$0.02B
Current Price:$0.00
Cap:$0.00B

Presented

Date05/11/2018
Price$16.76
Market Cap$0.02B
Ent Value$0.01B
P/E RatioN/A
Book ValueN/A
Div Yield0%
Shares O/S1.09M
Ave Daily Vol379,636
Short IntN/A

Current

Price$0.00
Market Cap$0.00B
Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay Madan in 2012 and is headquartered in Raleigh, NC.

Publicly traded companies mentioned herein: Innovate Biopharmaceuticals Inc (INNT)

Highlights

The presenter is long Innovate Biopharmaceuticals (INNT), which is the product of a recently completed reverse merger with Monster Digital (1/30/2018). The Raleigh, NC-based company’s pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis. Its lead drug candidate is larazotide acetate (INN-202) for celiac disease, and Phase 2b data were positive. Given the company’s path to the public market, a lack of sell side coverage, and questions about the dose, he sees an opportunity. With a market cap of just ~$420MM, a strong management team, and an asset set to start a Phase 3 trial this year, patient shareholders of INNT are likely to be rewarded.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.